Coronary artery disease is one of the most common diseases today and the primary cause of sudden death. The development of atherosclerosis and the incidence of symptomatic heart and vascular diseases increase depending on the average life expectancy in the elderly population. Stent applications in the treatment of coronary artery disease are quite widespread and are a standard procedure. Stent applications are applied to approximately 2 million people in the United States every year. Therefore, there is an increase in the number of patients with stents. This increase is an important and complex situation for patients who are planned for urological elective surgery. The necessity of treating the patient with the least morbidity and mortality, and supplying the balance in terms of the dose and duration of antiplatelet agents which are used for patients with stents who are planned for elective urological surgery, is main subject of our review. To whom and what should be the treatment are assessed accompanied by the literature.
Keywords: Antiplatelet therapy; Coronary stent; Elective urological surgery.